Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.

ESMO Open · 2021 · PMC8358417 · PMID 34371383

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significanceP = 0.054so close (0.05 < p ≤ 0.1)

27 The observed OS benefit in the ITT population ( n = 295) did not reach statistical significance with an HR of 0.74 (0.54-1.00; P = 0.054), which results in a downgrade to grade 2 for the ITT gBRCA -mutated population.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.